Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to usual care in a hospital setting.


Clinical Trial Description

Congestive heart failure has an exceptionally high rate of hospital admission and is responsible for more re-admissions (23.5% at 30 days) in the United States than the 2nd and 3rd leading causes combined. Inadequate medication reconciliation both on admission and discharge from the hospital is a significant cause of medical error. In one study of cardiovascular patients, 44% believed they were taking a medication they were not, and 96% were unable to recall at least one medication they were taking. In the same study patients omitted on average 6.8 medications from their medication list. Medication optimization through improved adherence and reconciled medical records has been postulated to significantly improve admission and 30-day hospital readmission rates.

Sano has developed a blood-based comprehensive medication monitoring tool that identifies and quantitates 235 prescription drugs and drug metabolites. It does not detect illicit drugs. This tool, which produces an output report designated the 'Patient Medication Profile', is designed to be used with clinical decision support to improve medication adherence, reduce medication errors, and optimize medication therapy. For heart failure patients, the investigators hypothesize that deploying the Patient Medication Profile with clinical decision support at key points of treatment intervention will A) improve medication adherence, B) identify and reconcile significant discrepancies in the medication list, C) result in reduced hospital admissions, and D) result in better overall patient outcomes. These outcome expectations are relative to usual care for heart failure patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03519477
Study type Interventional
Source Precera Bioscience, Inc.
Contact Scott Daniels
Phone 615-472-2549
Email jsdaniels@precera.com
Status Not yet recruiting
Phase N/A
Start date September 2018
Completion date November 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03202329 - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery N/A
Recruiting NCT02672618 - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology N/A
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03187470 - Left Ventricular Dyssynchrony in Multipole Pacing N/A
Recruiting NCT03385837 - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients N/A
Recruiting NCT03341156 - Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation Phase 3
Not yet recruiting NCT03575910 - HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Recruiting NCT03389386 - Plasma Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure
Recruiting NCT03671122 - PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study
Terminated NCT03102827 - High-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure Phase 3
Recruiting NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2
Recruiting NCT03078972 - Effect of mechanIcal circulatoRy Support ON Exercise Capacity aMong pAtieNts With Heart Failure
Recruiting NCT03573427 - LV Endocardial CRT for Patients With Intermediate QRS Width